In today’s recent session, 0.83 million shares of the Esperion Therapeutics Inc (NASDAQ:ESPR) have been traded, and its beta is 0.79. Most recently the company’s share price was $1.68, and it changed around -$0.06 or -3.16% from the last close, which brings the market valuation of the company to $333.38M. ESPR at last check was trading at a discount to its 52-week high of $3.94, offering almost -134.52% off that amount. The share price’s 52-week low was $1.47, which indicates that the recent value has risen by an impressive 12.5% since then. We note from Esperion Therapeutics Inc’s average daily trading volume that its 10-day average is 5.08 million shares, with the 3-month average coming to 4.25 million.
Esperion Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.62. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended ESPR as a Hold, whereas 3 deemed it a Buy, and 1 rated it as Underweight.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Instantly ESPR has been showing red trend so far today with a performance of -3.16% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.7500 on recent trading dayincreased the stock’s daily price by 4.0%. The company’s shares are currently down -23.41% year-to-date, but still up 6.65% over the last five days. On the other hand, Esperion Therapeutics Inc (NASDAQ:ESPR) is -7.42% down in the 30-day period. We can see from the shorts that 29.14 million shares have been sold at a short interest cover period of 9.11 day(s).
The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to increase their stock price by 79.0% from its current value. Analyst projections state that ESPR is forecast to be at a low of $8 and a high of $8.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.00% of Esperion Therapeutics Inc shares, and 65.72% of them are in the hands of institutional investors. The stock currently has a share float of 66.38%. Esperion Therapeutics Inc stock is held by 226.0 institutions, with WASATCH ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 8.9319% of the shares, which is about 16.86 million shares worth $37.44 million.
BLACKROCK INC., with 8.2617% or 13.98 million shares worth $31.04 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 6.68 shares worth $11.25 million, making up 3.37% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 6.18 shares worth around $10.41 million, which represents about 3.12% of the total shares outstanding.
